• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on: "The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022".

作者信息

de Vries Sieta T, Al-Mugoter Noral Huda S, Petkoska Irena, Verweij Stefan, Elferink André J A, Mol Peter G M

机构信息

Dutch Medicines Evaluation Board, Utrecht, The Netherlands.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

出版信息

Appl Health Econ Health Policy. 2024 Jan;22(1):123-124. doi: 10.1007/s40258-023-00850-4. Epub 2023 Nov 16.

DOI:10.1007/s40258-023-00850-4
PMID:37971664
Abstract
摘要

相似文献

1
Comment on: "The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022".关于《欧洲药品授权中患者报告结局的评估：2017年至2022年欧洲公共评估报告综述》的评论
Appl Health Econ Health Policy. 2024 Jan;22(1):123-124. doi: 10.1007/s40258-023-00850-4. Epub 2023 Nov 16.
2
The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022.在欧洲，对药品授权的患者报告结局评估：对 2017 年至 2022 年欧洲公共评估报告的回顾。
Appl Health Econ Health Policy. 2023 Nov;21(6):925-935. doi: 10.1007/s40258-023-00827-3. Epub 2023 Sep 2.
3
Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.引言或停止在欧洲药品生命周期中采取额外风险最小化措施。
Drug Saf. 2021 Jan;44(1):63-72. doi: 10.1007/s40264-020-00993-6.
4
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.向患者和临床医生传递抗癌药物的益处及其相关不确定性：对欧洲管制药品处方信息的文件分析。
BMJ. 2023 Mar 29;380:e073711. doi: 10.1136/bmj-2022-073711.
5
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.欧洲药品评估局批准的儿童用药。
Eur J Clin Pharmacol. 2002 Nov;58(8):495-500. doi: 10.1007/s00228-002-0511-0. Epub 2002 Sep 25.
6
Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022.2017-2022 年欧洲药品管理局批准用于神经疾病的药物的患者报告结局测量指标。
Neurol Sci. 2023 Aug;44(8):2933-2937. doi: 10.1007/s10072-023-06825-6. Epub 2023 May 5.
7
Marketing authorisation of orphan medicines in Europe from 2000 to 2013.2000 年至 2013 年在欧洲的罕见病药物的营销授权。
Drug Discov Today. 2018 Feb;23(2):424-433. doi: 10.1016/j.drudis.2017.10.012. Epub 2017 Oct 23.
8
Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.在东南欧国家授予药品营销许可：主管当局的观点。
Regul Toxicol Pharmacol. 2010 Jul-Aug;57(2-3):325-32. doi: 10.1016/j.yrtph.2010.04.001. Epub 2010 Apr 10.
9
The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.欧洲药品管理局批准的精神药物的证据基础：对所有欧洲公共评估报告的荟萃评估。
Epidemiol Psychiatr Sci. 2020 Apr 27;29:e120. doi: 10.1017/S2045796020000359.
10
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.欧洲新癌症药物的授权和资金审查时间到了吗？以奥拉单抗为例的推论。
Appl Health Econ Health Policy. 2020 Feb;18(1):5-16. doi: 10.1007/s40258-019-00527-x.

本文引用的文献

1
The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022.在欧洲，对药品授权的患者报告结局评估：对 2017 年至 2022 年欧洲公共评估报告的回顾。
Appl Health Econ Health Policy. 2023 Nov;21(6):925-935. doi: 10.1007/s40258-023-00827-3. Epub 2023 Sep 2.
2
Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs.新药产品特性摘要中关于患者报告结局的结果报告不足。
J Patient Rep Outcomes. 2021 Dec 7;5(1):127. doi: 10.1186/s41687-021-00402-1.
3
Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG.
健康相关生活质量测量在癌症临床试验中的附加值：NCIC CTG 的经验。
Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):119-28. doi: 10.1586/erp.10.15.